Q-omics provides the consensus-scored BRINP1 profile across patient tissues and cancer cell-line models. BRINP1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, BRINP1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, BRINP1 RNA expression shows 15,845 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LGG, THCA, and GBM as cancer lineages where BRINP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRINP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRINP1 survival associations across molecular data types. BRINP1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRINP1 RNA expression–survival associations across cancer types. High BRINP1 expression shows unfavorable associations in UCEC, HNSC and CESC, but favorable associations in LGG, PAAD and MESO. The LGG Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for BRINP1 RNA expression.
This table summarizes BRINP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for BRINP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRINP1 shows lower tumor expression in HNSC, BRCA, KICH, STAD and BLCA and higher tumor expression in THCA. The THCA box plot shows higher BRINP1 RNA expression in tumor versus normal tissue (log2 FC = +2.192, t-test p < 0.001).
This table shows molecular features associated with BRINP1 in patient tissues and cancer cell lines. In patient samples, BRINP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, BRINP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
